Windlas Biotech Limited — Updates, 10-01-2025: Press Release

Windlas Biotech Limited has received GMP certification for its new state-of-the-art injectable facility from the Food Safety & Drugs Administration Authority of Uttarakhand, following an inspection in December 2024. This certification reflects Windlas's adherence to WHO TRS Guidelines, reinforcing its reputation in the pharmaceutical manufacturing sector.

The Managing Director, Hitesh Windlass, emphasized that this marks a significant milestone in the company's growth, enhancing its capability to meet increasing domestic and global demand for high-quality injectable products. The facility boasts advanced technology and infrastructure, promoting operational excellence while ensuring environmentally friendly production processes.

With all five of its manufacturing plants now GMP-certified, Windlas Biotech is well-positioned to expand its product portfolio within the contract development and manufacturing organization (CDMO) sector, targeting a broader range of therapeutic areas, thereby improving patient access to essential medicines. This development presents a positive outlook for the company's strategic growth and operational capacity in the competitive pharmaceutical landscape.